SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as GBX 5 and last traded at GBX 5.28, with a volume of 74,904 shares traded. The stock had previously closed at GBX 5.25.
SkinBioTherapeutics Price Performance
The company’s fifty day moving average is GBX 7.10 and its two-hundred day moving average is GBX 10.18. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14. The firm has a market cap of £13.67 million, a price-to-earnings ratio of -32.97 and a beta of 0.10.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
